{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-011642","form_type":"8-K","ticker":"COCP","cik":"0001412486","company_name":"Cocrystal Pharma, Inc.","filed_at":"2023-04-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.769544+00:00","generated_at":"2026-06-17T04:02:58.818918+00:00","sec_items":["1.01","3.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Cocrystal Pharma completes $4M private placement of common stock at $1.97/share","bullets":["Sold 2,030,458 shares at $1.97 each for total proceeds of $4.0 million.","Investors: director/co-founder Phillip Frost and Fred Hassan (Caret Group, Warburg Pincus), each investing $2.0 million.","Net proceeds to advance preclinical/clinical antiviral programs and for working capital.","Company preparing for Phase 2a influenza A study (CC-42344) and first-in-human COVID-19 trial (CDI-988) in 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-011642","json":"https://secwatch.observer/filing/0001493152-23-011642.json","markdown":"https://secwatch.observer/filing/0001493152-23-011642.md","text":"https://secwatch.observer/filing/0001493152-23-011642.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1412486/000149315223011642/0001493152-23-011642-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1412486/000149315223011642/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T04:02:58.818918+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"00336c16e73666dfdd0ce97f68fb84cc3bd89934","claim":"Cocrystal Pharma, Inc. entered into Securities Purchase Agreement with Fred Hassan and Frost Gamma Investments Trust valued at $4,000,000 (effective 2023-04-04).","evidence_excerpt":"On April 4, 2023, Cocrystal Pharma, Inc. (the “Company”) entered into a Securities Purchase Agreement (“SPA”) with two accredited investors (the “Purchasers”) whereby the Purchasers agreed to purchase a total of 2,030,458 shares of common stock at a price of $1.97 per share for a total purchase price of $4,000,000 in two equal $2,000,000 investments.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315223011642/0001493152-23-011642-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"Fred Hassan and Frost Gamma Investments Trust"},{"label":"Value","value":"$4,000,000"},{"label":"Effective","value":"2023-04-04"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}